Evidence map›Paper›PMID 40796927›Full record

ArticleScientific reports2025

CPS1-promoted the progression of lung adenocarcinoma via suppressing ammonia induced the activation of ROS/AMPK/P53/LKB1 signaling pathway.

Yanchao Luan, Liru Liu, Jiakun Liu, Li Zhao, Chao Liang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanchao Luan *Hebei Provincial Key Laboratory of Lung Diseases, Department of Thoracic Surgery, Hebei Provincial Chest Hospital, No. 372, Shengli North Street, C hang'an District, Shijiazhuang, 050011, Hebei, China.
Liru Liu *Hebei Provincial Key Laboratory of Lung Diseases, Department of Thoracic Surgery, Hebei Provincial Chest Hospital, No. 372, Shengli North Street, C hang'an District, Shijiazhuang, 050011, Hebei, China.
Jiakun LiuHebei Provincial Key Laboratory of Lung Diseases, Department of Thoracic Surgery, Hebei Provincial Chest Hospital, No. 372, Shengli North Street, C hang'an District, Shijiazhuang, 050011, Hebei, China.
Li ZhaoHebei Provincial Key Laboratory of Lung Diseases, Department of Thoracic Surgery, Hebei Provincial Chest Hospital, No. 372, Shengli North Street, C hang'an District, Shijiazhuang, 050011, Hebei, China.
Chao LiangHebei Provincial Key Laboratory of Lung Diseases, Department of Thoracic Surgery, Hebei Provincial Chest Hospital, No. 372, Shengli North Street, C hang'an District, Shijiazhuang, 050011, Hebei, China. liang15632331167@126.com.

Funding

2024 Government Funding for Excellence in Clinical Medicine Project ZF2024175
6 · The paper itself

Abstract

This study aims to explore how CPS1 influences the progression of lung adenocarcinoma by affecting the ammonia-induced ROS/AMPK/P53/LKB1 signaling pathway. Bioinformatics analysis was conducted to identify differential gene expression in lung adenocarcinoma patients. A549 cells were infected with control (NC) or CPS1 knockdown (CPS1-KD) lentivirus. Cells were treated with or without AMPK agonists, AMPK inhibitors, P53 agonists, or P53 inhibitors, followed by Western blot analysis of CPS1, NOX2, NOX4, p-AMPK, p-P53, and LKB1 protein levels. The content of MDA and SOD was measured, and the expression of AMPK, caspase-3 and P53 in tumor cells was detected through immunofluorescence. Apoptosis-related protein expression and tumor cell apoptosis were assessed using Western blot and flow cytometry. Tumor cell proliferation was evaluated using CCK-8 assays and colony formation experiments. Tumor size was measured in xenograft models using nude mice. Bioinformatics analysis indicated that LKB1 positively regulates AMPK activity. CPS1 knockdown results in increased ammonia levels, with upregulated expression of NOX2, NOX4, p-AMPK, p-P53, and LKB1 in tumor cells. Elevated P53 levels, along with significant increases in Bax, Caspase-8,and Caspase-12 expression, were observed, promoting apoptosis and inhibiting tumor cell proliferation. AMPK and P53 act to inhibit lung adenocarcinoma progression. CPS1 promotes the progression of lung adenocarcinoma by suppressing ammonia-induced activation of the ROS/AMPK/P53/LKB1 signaling pathway.

Indexed as

Adenocarcinoma of LungAmmoniaAMP-Activated Protein KinasesLung NeoplasmsProtein Serine-Threonine KinasesReactive Oxygen SpeciesSignal TransductionTumor Suppressor Protein p53A549 CellsAMP-Activated Protein Kinase KinasesAnimalsApoptosisCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticAmmoniaAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesProtein Serine-Threonine KinasesReactive Oxygen SpeciesSTK11 protein, humanTP53 protein, humanTumor Suppressor Protein p53AMPKCPS1LKB1P53ROS

Identifiers

PMID40796927
PMCPMC12343839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.